PAHC PHIBRO ANIMAL HEALTH CORP Insider Trading

Director E Thomas Corcoran buys 10,000 PAHC shares at $31.77; stock now $28.52, -52.5% from 52-week high

E Thomas Corcoran, a PAHC director, purchased 10,000 shares at $31.77 on 2026-05-29, increasing his holdings to 41,459 shares (a 31.8% increase). The transaction occurs against a backdrop of significant recent weakness: the stock trades at $28.52, down 52.5% from its 52-week high of $60.08 and down 48.0% over the past 30 days. Corcoran's prior two purchases at PAHC both posted positive 90-day returns (5.2% and 16.2%), suggesting his historical timing at this ticker has been favorable. The company's underlying fundamentals remain solid—revenue of $383.5M, net income of $24.0M, annual revenue growth of 27.4%, and a P/E of 20.67—yet the stock's sharp recent decline stands in stark contrast. This purchase represents an open-market commitment of capital during a period of substantial drawdown, though whether it reflects conviction or represents a discretionary tactical move cannot be determined from the transaction data alone.

CEO and 10% owner Jack Bendheim sells over $1M of PAHC shares across 7 transactions; all prior sales on this stock poorly timed as shares rose afterward.

Jack Bendheim, President, CEO, and 10% beneficial owner of Phibro Animal Health, divested over $1 million in shares across seven separate transactions over three trading days, reducing his holdings by roughly 18,600 shares. This marks his third major selling cycle in recent weeks—his two most recent sale batches just days earlier both saw the stock rise significantly afterward, a pattern consistent across all five of his prior sales on this ticker. The CEO is selling into strength: the stock trades near its recent highs and has staged a strong recovery over the past three months, making this timing notably different from his past sales, which typically preceded gains rather than pullbacks. Phibro remains a profitable, revenue-growing company, so this divestiture does not signal financial distress; rather, it represents a material reduction in Bendheim's personal exposure to a stock that has climbed substantially and at which he has been a net seller for months. Retail investors should note that concentrated insider selling—especially by a founder-aligned 10% owner—typically warrants closer examination, particularly when the seller's track record shows poor timing on similar exits.